Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10166040 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TDP1MMP1MMP2MMP3 | |
| SCHEMBL24221392 | 0.82 | HDAC7 (0.35) | TDP1TSHR | |
| SCHEMBL10166039 | 0.82 | HDAC7 (0.35) | TDP1TSHR | |
| SCHEMBL25777637 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13213430 | 0.81 | TGFBR1 (0.34) | TDP1TSHR | |
| SCHEMBL12766316 | 0.81 | TGFBR1 (0.34) | TDP1TSHR | |
| SCHEMBL19361692 | 0.79 | TDP1 (0.30) | TDP1 | |
| SCHEMBL18932853 | 0.79 | ALDH1A1 (0.32) | ALDH1A1TDP1TSHR | |
| SCHEMBL12766327 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MMP2 | |
| SCHEMBL24494714 | 0.79 | ACE (0.39) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242586-A1 | RAS INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-9012603-B2 | Peptides that block the binding of IgG to FcRn | BIOGEN IDEC HEMOPHILIA INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8912146-B2 | Derivatives of APF and methods of use | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-12-16 | — | — | US | disclosed |
| US-20120094933-A1 | DERIVATIVES OF APF AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-19 | — | — | US | disclosed |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | ALDH1A1 2370/4885TDP1 2985/4885MMP1 2876/4885 |
| US-20230242586-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 4073/4885TDP1 2509/4885MMP1 2093/4885 |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | ALDH1A1 4835/4885TDP1 4331/4885MMP1 3010/4885 |
| US-20120094933-A1 | DERIVATIVES OF APF AND METHODS OF USE | APLNR, ETF1, VIP | ALDH1A1 1595/4885TDP1 3052/4885MMP1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.